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ENERGETICS AND MECHANISM OF DRUG
TRANSPORT MEDIATED BY THE LACTOCOCCAL
MULTIDRUG TRANSPORTER LmrP
Henk Bolhuis, Hendrik W. van Veen, Jan Roel Brands, Monique Putman,
Bert Poolman, Arnold J.M. Driessen and Wil N. Konings
The gene encoding the secondary multidrug transporter LmrP of Lactococcus lactis was
heterologously expressed in Escherichia coli. The energetics and mechanism of drug
extrusion mediated by LmrP were studied in membrane vesicles of E. coli. LmrP mediated
extrusion of tetraphenyl phosphonium (TPP ) from right-side-out membrane vesicles and+
uptake of the fluorescent membrane probe TMA-DPH into inside-out membrane vesicles
are driven by the membrane potential ()R) and the transmembrane proton gradient ()pH),
pointing to an electrogenic drug/proton antiport mechanism. Ethidium bromide, a substrate
for LmrP, inhibited the LmrP mediated TPP  extrusion from right-side-out membrane+
vesicles, showing that LmrP is capable of transporting structurally unrelated drugs. Kinetic
analysis of LmrP-mediated TMA-DPH transport revealed a direct relation between the
transport rate and the amount of TMA-DPH associated with the cytoplasmic leaflet of the
lipid bilayer. This observation indicates that drugs are extruded from the inner leaflet of the
cytoplasmic membrane into the external medium. This is the first report that shows that drug
extrusion by a secondary MDR transporter occurs by a "hydrophobic vacuum cleaner"
mechanism in a similar way as was proposed for the primary lactococcal MDR transporter,
LmrA.




Infections by pathogenic bacteria can often successfully be treated with antibiotics.
A major drawback of the widespread use of antibiotics, however, is posed by the selection
of antibiotic resistant strains. Different mechanisms of antibiotic resistance have evolved
which comprise : (i) the enzymatic inactivation of the antibiotics, (ii) the alteration of the
drug target, (iii) the prevention of drug entry by alterations in the cell envelope, and (iv) the
active extrusion of the drugs from the cell (Nikaido, 1994). Active drug extrusion can be
mediated by specific drug resistance (SDR) transporters as well as by multidrug resistance
(MDR) transporters; the latter systems confer resistance to a broad range of unrelated toxic
compounds (Endicott and Ling, 1989).
To date, several bacterial drug extrusion systems have been identified and
characterized at the genetic level (for reviews see Nikaido, 1994, van Veen et al., 1996).
The bacterial drug extrusion systems can be divided into: (i) secondary drug transporters
which mediate drug extrusion in a coupled exchange with protons (Paulsen and Skurray,
1993), and (ii) ATP-binding cassette (ABC)-type drug transporters which utilize the free
energy of ATP hydrolysis to extrude cytotoxic substrates (Fath and Kolter, 1993, Higgins,
1992). The secondary drug transporters are subdivided into two groups on the basis of
their similarity in size and secondary structure (Schuldiner et al., 1995). The largest
subgroup, termed TEXANs (Toxin EXtruding ANtiporter), consists of integral membrane
proteins with 12 to 14 putative transmembrane spanning segments and an average
molecular weight of 45 to 50 kDa (van Veen et al., 1996; Lewis, 1994; Marger and Saier,
1993; Saier et al., 1994). The second subgroup comprises the mini TEXANs which share
functional similarity with the TEXANs but are much smaller (12-15 kDa) and form only 4
putative transmembrane "-helices (Yerushalmi et al., 1995; Grinius and Goldberg, 1994).
In Lactococcus lactis, two distinct transport systems (LmrP and LmrA) have been
identified which mediate active extrusion of multiple cationic drugs (Chapter II). LmrP is
a secondary drug transporter comprising 408 amino acid residues with 12 putative
membrane spanning segments (Chapter III). The protein is homologous to several drug
transporters belonging to the group of TEXANs. The second multidrug transporter, LmrA,
is a 589-amino acid integral membrane protein and belongs to the ATP-binding cassette
(ABC) family of drug transporters (Chapter V). Most strikingly, LmrA is the first example of
a bacterial ATP-dependent multidrug extrusion system in which both functional and
structural properties of the human MDR1 gene encoded MDR transporter P-glycoprotein
(P-gp) are united.
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The involvement of the )p as a driving force for multidrug extrusion by TEXAN
members has not been studied extensively. Instead, this characteristic of TEXANs is based
on the inhibition of drug transport by protonophores like CCCP, and on their structural
similarity to other secondary transport systems (Neyfakh et al., 1991; Yoshida et al., 1990;
Lomovskaya and Lewis, 1992). We have now studied the energetics and mechanism of
drug transport by LmrP in membrane vesicles of E. coli expressing the protein. Evidence
is presented that LmrP mediates drug transport via an electrogenic mechanism in which
drugs are expelled from the inner leaflet of the phospholipid bilayer. 
Materials and methods
Growth of the organisms. Bacterial strains and plasmids used in this study are
listed in Table 1. Lactococcus lactis strains were grown at 30EC on M17 medium (Difco)
supplemented with glucose (25 mM) and erythromycin (5 µg/ml) when needed. E. coli was
grown aerobically at 37EC on Luria Broth (Sambrook et al., 1989) with carbenicillin (50
µg/ml) and IPTG when needed.
DNA manipulation and construction of H-LmrP. General procedures for cloning
and DNA manipulations were performed essentially as described by Sambrook et al.
(1989). In order to subclone lmrP, the gene was amplified from the chromosome of L. lactis
MG1363 via the polymerase chain reaction as described previously (Chapter III). The
amino-terminal polyhistidine (His)-tag containing LmrP derivative H-LmrP was constructed
by subcloning the lmrP containing PCR fragment in frame with a His-tag encoding6
sequence in the E. coli expression vector pET302 (Manting, van der Does and Driessen,
submitted), and transformation of ligated DNA to E. coli DH5". The different cloning steps
were checked by restriction analysis and double-stranded DNA sequencing using the
dideoxy chain-termination procedure (Sanger et al., 1977) and the T7 DNA sequencing kit
(Pharmacia). 
Preparation of membrane vesicles. E. coli DH5" was grown aerobically at 37°C
to an A  of about 0.8 on Luria Broth supplemented with carbenicillin (50 µg/ml) plus IPTG60
(100 µg/ml) when appropriate. Inside-out (ISO) (Ambudkar et al., 1984) and right-side-out
(RSO) (Kaback, 1971) membrane vesicles were prepared as described and resuspended
in 50 mM potassium HEPES (pH 7.0) containing 5 mM MgSO (ISO), or in 50 mM4
potassium phosphate (pH 7.0) containing 5 mM MgSO (RSO). Membrane vesicles were4
stored in liquid nitrogen. 
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Purification of H-LmrP. H-LmrP was partially purified via Ni-NTA agarose affinity
chromatography (QIAGEN Inc., USA). Membrane vesicles (5 mg of protein) were
solubilized in 3.5 ml buffer A [50 mM sodium phosphate (pH 8.0) plus 600 mM NaCl, 10
mM Tris/HCl, and 20% v/v glycerol] plus Triton X-100 (1% w/v) for 30 min at room
temperature. Subsequently, the mixture was centrifuged (15 min, 350,000 × g at 4EC) and
the supernatant was gently mixed with 200 µl of a 50% Ni-NTA resin slurry (100 µl column
material) for 30 min at room temperature, after which the suspension was poured into a
column. The column was subsequently washed with 20 column volumes of buffer A plus
0.5% (w/v) Triton X-100 (buffer B), followed by 50 column volumes of buffer B plus 10 mM
imidazole, and 5 column volumes of buffer B plus 25 mM imidazole. Finally, H-LmrP was
eluted from the column with 5 volumes of buffer B plus 250 mM imidazole and the total
fraction (500 µl) was collected. The fractions were analyzed by SDS-PAGE (Laemmli,
1970).
TMA-DPH transport in ISO membrane vesicles. The amount of membrane
associated TMA-DPH (Molecular Probes Inc., Eugene, OR, USA) was measured
fluorimetrically as described (Chapter VI). ISO membrane vesicles prepared from E. coli
DH5" (0.4 mg protein/ml) were suspended in oxygen-saturated 50 mM potassium HEPES
(pH 7.5) containing 25 mM KSO plus 5 mM MgSO. A )p (inside positive and acidic) was2 4 4
generated by the oxidation of D-lactate via a constitutively expressed, membrane
associated lactate dehydrogenase (van Schie et al., 1985). The fluorescence development
upon addition of TMA-DPH (100 nM, final concentration) was recorded in time using
excitation and emission wavelengths of 350 and 425 nm, and slit widths of 5 and 10 nm,
respectively.
TPP  accumulation in RSO membrane vesicles. Tetraphenyl phosphonium+
(TPP ) accumulation in RSO membrane vesicles was calculated from the external free+
probe concentration as recorded by a TPP  selective electrode (Shinbo et al., 1978). In+
competition experiments, ethidium bromide was added prior to TPP  to correct for+
changes in the electrode output. RSO membrane vesicles were resuspended in potassium
phosphate (pH 6.8) containing 5 mM MgSO to a final concentration of 0.3 mg protein/ml.4
A )p (inside negative and alkaline) was generated by oxidation of glucose (10 mM) via the
membrane bound pyrrolo-quinoline quinone (PQQ)-dependent glucose dehydrogenase of
E. coli (van Schie et al., 1985). PQQ was added to a final concentration of 1 µM.
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Table 1
Bacterial strains and plasmids
Bacterium/plasmid Relevant characteristics Source/refs.
Bacterium
L. lactis
MG1363 ML3, plasmid free, Lac, Prt Gasson (1983)- -
E. coli
DH5" supE44,hsdR17,recA1,endA1, gyrA96, thi-1, BRL Inc., Bethesda
relA1, )lacU169 (*80LacZ)M15)
Plasmids
pBluescript SKII Ap, expression vector Stratagene- R
pSKLMR3.2 pBluescript SK II, carrying lmrP of L. lactis on a (Chapter III)-
3.2 kb HindIII fragment
pGK13 Em, Cm, E. coli-L. lactis shuttle vector Kok et al. (1984)R R
pGKLMR3.2 pGK13, carrying lmrP of L. lactis on a 3.2 kb (Chapter III) 
HindIII fragment pTRC99A
Ap, pBR322 derivative containing trc promoter PharmaciaR
pET302 pTRC99A carrying a His-tag coding region and van der Does (submitted)
trc promoter 





Heterologous expression of LmrP and identification of the protein. LmrP was
heterologously expressed in E. coli strain DH5" using the plasmid vector pET302 on which
LmrP was transcribed from the trc promoter. To evaluate the expression of LmrP in E. coli,
a His-tag was engineered at the amino-terminus of the protein, yielding H-LmrP, which
allows detection of the protein after purification by Nickel-NTA chromatography. Fig. 1
shows that H-LmrP corresponds to a protein with an apparent molecular mass of 35 kDa
on SDS-PAGE. 
Fig. 1. Expression of H-LmrP in E.
coli and identification of the protein.
Silver stained 10% SDS-PAGE containing
samples of total membranes (lanes 1 & 2) and
Ni-NTA eluates (lanes 3 & 4) from cells
harboring the control vector pET302 (lane 1 & 3)
or the H-LmrP encoding vector pHLP1 (lane 2 &
4). Lane 5, molecular weight markers; the arrow
indicates the position of H-LmrP.
H-LmrP mediated TPP  extrusion. To asses the functional expression of H-LmrP+
in E. coli, tetraphenyl phosphonium (TPP ) efflux by isolated RSO membrane vesicles was+
monitored using an ion selective electrode. Generation of a )R (inside negative) by
glucose oxidation, in the presence or absence of the potassium/proton ionophore nigericin,
resulted in a high accumulation of TPP  in control RSO membrane vesicles (Fig. 2;+
pET302). The )R-driven passive influx of TPP  was much lower in RSO membrane+
vesicles containing H-LmrP (Fig. 2; pHLP1). Importantly, measurements of )R by the
fluorescent probe DiSC(5) revealed comparable values for the control and LmrP containing3
RSO membrane vesicles (data not shown), indicating that differences in TPP +
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accumulation are most likely  due  to  active  extrusion  of  TPP   via H-LmrP. +
Fig. 2. TPP accumulation in right-side-out membrane vesicles of E. coli DH5". The+
accumulation of TPP in RSO membrane vesicles of E. coli DH5"/pET302 (control) and DH5"/pHLP1 (H-+
LmrP) was followed by recording the external free TPP concentration with an ion selective electrode.+
Measurements were carried out in potassium phosphate (50 mM, pH 6.8) containing 5 mM MgSO plus 44
µM TPP at 30°C. The additions of RSO membrane vesicles (0.3 mg of protein/ml), 2 µM of PQQ plus 10 mM+
of glucose, 1 µM of nigericin, and 1 µM of valinomycin are indicated by arrows. Reserpine was included in
the phosphate buffer at a final concentration of 10 µg/ml when indicated in the figure. 
An enhanced )R-driven uptake of TPPwas observed in pHLP1 RSO membrane vesicles in+ 
[Ethidium]  (µM)









the presence of reserpine (Fig. 2), a
known inhibitor of LmrP and other
MDR transporters (Chapter III,
Ahmed et al., 1993). The TPP+
accumulation in the presence of
reserpine was similar for the control
and H-LmrP containing RSO
membrane vesicles. 
Fig. 3.  Ethidium bromide and
TPP compete for LmrP-mediated+
extrusion. TPP accumulation as function+
of the ethidium concentration was assayed
in H-LmrP containing pHLP1 RSO
membrane vesicles (O), pHLP1 RSO
membrane vesicles plus reserpine (G) and
in the control pET302 RSO membrane
vesicles (M) as described in the legend to
Fig. 2. The maximal TPP accumulation was+
calculated from the difference in recorder output before and after dissipation of the membrane potential with
valinomycin.
These data show that the decreased TPP  accumulation in pHLP1 RSO membrane+
vesicles results from LmrP-mediated TPP  extrusion. In previous experiments we have+
shown that ethidium bromide is a substrate for LmrP (Chapter III). In accordance with this
observation, the accumulation of TPP  in pHLP1 RSO membrane vesicles was enhanced+
in the presence of increasing concentrations of ethidium bromide, whereas TPP +
accumulation was not affected by ethidium bromide in control RSO membrane vesicles or
in pHLP1 RSO membrane vesicles plus reserpine (Fig. 3). These experiments
demonstrate that H-LmrP is functionally expressed in E. coli.
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Fig. 4. TMA-DPH transport in inside-out membrane vesicles of E. coli DH5". Uptake
of TMA-DPH (100 nM, final concentration) was followed fluorometrically in an aerated buffer containing ISO
membrane vesicles (0.4 mg of protein/ml) of E. coli DH5" harboring pHLP1 or pET302. The fluorescence
development was assayed in: (a) non-energized ISO membrane vesicles, (b) ISO membrane vesicles
energized with 10 mM of D-lactate, (c) as b plus 10 µg of reserpine/ml, and (d) as b preincubated with 1 µM
of nigericin. Valinomycin was added to a final concentration of 1 µM as indicated (val).
Energetics of LmrP-mediated drug transport. The H-LmrP mediated extrusion of TPP in+
the presence of nigericin (Fig. 2) indicates that the )R can function as the sole driving force for
efflux. To study the energetics of LmrP in greater detail, TMA-DPH transport was measured in
ISO membrane vesicles of E. coli DH5" in which an inversed )p (inside acidic and positive) was
generated by the oxidation of D-lactate. TMA-DPH is an amphiphilic, cationic and hydrophobic
membrane probe (partition coefficient in octanol/water of 2.4 × 10 ), which is only fluorescent5
when present in the membrane (Prendergast et al., 1981). 
Therefore, the fluorescence properties of TMA-DPH can be directly used to follow the
concentration of the probe in the lipid bilayer by means of fluorescence spectrophotometry
(Kuhry et al., 1985). TMA-DPH added to pre-energized pHLP1 ISO membrane vesicles
exhibited a rapid increase in TMA-DPH fluorescence, which was immediately followed by
a fluorescence decrease. These results indicate that TMA-DPH inserts rapidly into the
membrane and, subsequently, translocates from the membrane into the intravesicular
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space (Fig. 4). Importantly, TMA-DPH transport into the intravesicular space was partially
inhibited upon dissipation of the )pH by nigericin or by dissipation of the )R by the
potassium ionophore valinomycin. Complete inhibition of TMA-DPH transport was
observed by (i) total dissipation of the )p by nigericin plus valinomycin, and (ii) complete
inhibition of LmrP activity by reserpine. In the control ISO membrane vesicles, TMA-DPH
fluorescence was not affected by dissipation of the )p or addition of reserpine (Fig. 4).
These experiments clearly demonstrate that both the )R and the )pH function as a driving
force of LmrP-mediated drug transport.
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Fig. 5. Rate of energy-dependent TMA-DPH extrusion in the course of TMA-DPH
partitioning in the phospholipid bilayer. Energy dependent TMA-DPH fluorescence development
in cells of L. lactis MG1363/pGKLMR3.2 (A) and in ISO membrane vesicles of E. coli DH5"/pHLP1 (B).
Cells and ISO membrane vesicles were energized with 25 mM of glucose or 10 mM of D-lactate,
respectively, 3 min prior to the addition of 100 nM of TMA-DPH, or after this addition at the time points
indicated. The dashed line represents the steady state level of TMA-DPH fluorescence. 
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Kinetics of LmrP-mediated TMA-DPH transport. The kinetics of TMA-DPH
fluorescence development upon the addition to cells is biphasic (Chapter VI) (see also Fig.
4). The initial fast phase reflects probe partitioning in the outer leaflet of the membrane,
while the second and slower phase is due to the transbilayer movement of TMA-DPH into
the inner leaflet of the membrane. In L. lactis Eth  cells overexpressing the ATP-dependentR
MDR-transporter, the initial TMA-DPH extrusion rate correlates with the amount of probe
associated with the cytoplasmic leaflet (Chapter VI), suggesting that LmrA extrudes the
TMA-DPH from the inner leaflet of the lipid bilayer. As shown in Fig. 5A, similar results are
obtained when L. lactis cells are used that overexpress LmrP. The initial rate of TMA-DPH
extrusion increases in the course of probe flipping from the outer to the cytoplasmic leaflet
of the membrane, whereas the steady-state TMA-DPH fluorescence level remains the
same (Fig. 5A). The initial TMA-DPH extrusion rate increased in the course of probe
flipping from the external to the cytoplasmic leaflet of the membrane, whereas the steady
state TMA-DPH fluorescence levels reached similar values (Fig. 5A). In pHLP1 ISO
membrane vesicles, however, the initial transport rates were identical and independent of
the partitioning of TMA-DPH into the internal leaflet of the inverted membrane system. The
steady state TMA-DPH fluorescence in this experiment increased along with the
partitioning of TMA-DPH into the internal leaflet of the membrane (Fig. 5B). The observed
kinetics of TMA-DPH transport in whole cells and ISO membrane vesicles further
demonstrate that the rate of TMA-DPH transport depends on the amount of probe
associated with the cytoplasmic leaflet of the membrane.
Discussion.
The energetics and mechanism of LmrP-mediated drug extrusion have been studied
in membrane vesicles of E. coli DH5" in which LmrP was functionally expressed. The lack
of TPP  accumulation in pHLP1 RSO membrane vesicles upon generation of a )p and the+
restoration of TPP accumulation, up to levels observed in the control RSO membrane+
vesicles, upon addition of reserpine (Fig. 2) demonstrate that TPP  extrusion is LmrP-+
mediated. In addition, the competition between TPP  and ethidium bromide for LmrP+
mediated transport (Fig. 3) is in agreement with our previous conclusion that multidrug
resistance and transport of various unrelated drugs by L. lactis correlate with the over-
expression of LmrP (Chapter III). The slight enhancement of TPP  accumulation in the+
control RSO membrane vesicles upon addition of reserpine points to the presence of a low
endogenous TPP  transport activity in E. coli. Indeed, genes specifying MDR transporters+
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such as the miniTEXAN EmrE (Yerushalmi et al., 1995), and the TEXANs EmrAB
(Lomovskaya and Lewis, 1992) and AcrAB (Ma et al., 1995) are present in E. coli. Low
level expression of one or more of these proteins might be responsible for the extrusion of
TPP . Therefore, in general, data obtained from the transmembrane distribution of+
lipophilic cations like TPP , or other probes that report changes in the )p (Molenaar et al.,+
1992), have to be treated with caution as these probes might be recognized by
endogenous MDR transporters.
To study the energetics and mechanism of LmrP-mediated drug transport in greater
detail, the fluorescent membrane probe TMA-DPH was used as a model substrate.
Preliminary studies in whole cells of L. lactis MG1363 expressing LmrP indicated that
TMA-DPH is a substrate for LmrP (unpublished results; Fig. 5A). Consistent with this,
LmrP-mediated TMA-DPH uptake could be measured in pHLP1 ISO membrane vesicles,
while no transport was observed in the control ISO membrane vesicles (Fig. 4). The role
of LmrP in the transport of TMA-DPH was confirmed by the complete inhibition of TMA-
DPH transport by reserpine. The generation of a )R (inside positive) and/or )pH (inside
acidic) in pHLP1 ISO membrane vesicles resulted in a significant decrease of TMA-DPH
fluorescence and indicated that LmrP-mediated drug transport is driven by both
components of the )p. In view of the charge of the transported drugs, being monovalent
cationic, the data strongly suggest drug transport via an electrogenic drug/nH  (n$2)+
antiport mechanism. A similar mechanism was proposed for the miniTEXANs Smr (Grinius
and Goldberg, 1994) and EmrE (Yerushalmi et al., 1995). Surprisingly, this mechanism
differs from that of the LmrP homolog TetA, which mediates the electroneutral exchange
of a positively charged tetracycline-metal complex for one proton (McMurry et al., 1980,
Yamaguchi et al., 1990), despite the fact that LmrP confers resistance to tetracycline as
well (unpublished results).
The initial rate of LmrP-dependent TMA-DPH transport correlates with the amount
of TMA-DPH in the inner membrane leaflet of whole cells, and with the amount of TMA-DPH
in the outer leaflet of ISO membrane vesicles (Fig. 5). Since the outer membrane leaflet of
inversely oriented ISO membrane vesicles corresponds to the cytoplasmic leaflet in vivo,
both observations rule out the external leaflet of the cytoplasmic membrane as possible site
of drug binding to LmrP. Fig. 6 summarizes our current view of LmrP mediated drug
transport as depicted for TMA-DPH. The association of TMA-DPH with lipid bilayers and
the concomitant fluorescence development has been extensively studied (Chapter VI,
Prendergast et al., 1981, Kuhry et al., 1985). Due to the charged TMA-moiety, TMA-DPH
is restrictively oriented perpendicular to the surface of the membrane. Since the TMA-DPH
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partitioning is highly asymmetric on a time scale of several minutes, in which the fast
partitioning of TMA-DPH in the external leaflet of the membrane is followed by a slow
passive transbilayer movement of TMA-DPH to the trans face, it was possible to follow the
redistribution of the probe over both membrane leaflets.
Fig. 6. Proposed mechanism of LmrP mediated TMA-DPH extrusion.
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As was shown previously, the passive release of TMA-DPH from the membrane into the
aqueous space is a slow process (Chapter VI), suggesting the presence of an energy
barrier at the membrane water interface. This notion is consistent with the slow desorption
of phospholipids from the vesicle surface (Bielicki et al., 1991). In terms of MDR, the slow
passive release from the membrane of amphiphilic cationic drugs would favour a
mechanism in which drugs are directly transported from the cytoplasmic leaflet of the
membrane into the external medium. Indeed this is what is observed for the initial LmrP-
mediated TMA-DPH transport into ISO membrane vesicles. A fluorescence decrease
rather than an increase is observed when LmrP is active (Fig.5B). The latter would be
expected when drugs are actively translocated from the cytoplasmic to the external leaflet
of the membrane followed by passive diffusion into the external medium. 
LmrP mediated TMA-DPH extrusion from the inner leaflet into the external medium
is consistent with the "hydrophobic vacuum cleaner" model (Mülder et al., 1993; Higgins
and Gottesman, 1992; Gros et al., 1986; Raviv et al., 1990; Gottesman and Pastan, 1993)
which predicts that hydrophobic drugs are most efficiently transported from the
compartment where the transporter encounters the highest substrate concentration, i.e.,
from the membrane. Our studies suggest a role for MDR-type transporters in maintaining
membrane integrity, which is important since several hydrophobic compounds are known
to be toxic at the membrane level (Barabas et al., 1992, Sikkema et al., 1995).
Interestingly, the mechanism of drug extrusion by LmrP is similar to that of the ATP-
dependent drug transporter LmrA of L. lactis (Chapter VI). This shows that despite of a
different mechanism of energy coupling to drug transport ()p versus ATP hydrolysis), these
non-homologous proteins may share similar structural features involved in drug extrusion
from the cytoplasmic leaflet of the membrane. These features are likely to be present in
other MDR transporters as well, including the human P-glycoprotein (Smit et al., 1993;
Homolya et al., 1993; Ruetz and Gros, 1994; Stein et al., 1994; Shapiro and Ling, 1995a).
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